TNXP— Tonix Pharmaceuticals Holding Corp.

MaterialsPharmaceutical Preparations$192M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Product revenue, net	$13.1M+29.8%	$10.1M+29.9%	$7.8M	—
Cost of sales	$6.6M-14.5%	$7.8M+63.8%	$4.7M	—
Research and development	$44.5M+11.3%	$40.0M-53.9%	$86.7M+5.8%	$81.9M
Selling, general and administrative	$87.7M+118.7%	$40.1M+15.4%	$34.8M+15.0%	$30.2M
Asset impairment charges	$59.0M	—	—	—
Total Operating Expenses	$138.8M-5.4%	$146.8M+16.4%	$126.1M+12.5%	$112.1M
Operating loss	-$125.7M+8.0%	-$136.7M-15.5%	-$118.4M-5.6%	-$112.1M
Grant income	$3.0M+16.1%	$2.6M	—	—
Gain on change in fair value of warrant liabilities	$6.2M	—	—	—
Loss on extinguishment of debt	-$2.1M	$0	—	—
Interest income	$4.1M+18745.5%	$22K	—	$1.9M
Interest expense	-$89K+92.8%	-$1.2M	—	—
Other expense, net	-$3.3M-280.0%	-$867K-150.3%	$1.7M	—
Net loss available to common stockholders	-$124.0M+4.6%	-$130.0M-11.5%	-$116.7M+0.2%	-$116.9M
Net loss to common stockholders per common share, basic	-$14570.00+91.7%	-$176600.00+98.8%	-$14720250.00-73464.5%	-$20010.00
Net loss to common stockholders per common share, diluted	-$14570.00+91.7%	-$176600.00+98.8%	-$14720250.00-73464.5%	-$20010.00
Weighted average common shares outstanding, basic	8.51B+1055.9%	736.3M+9191.3%	7.9M-99.9%	5.84B
Weighted average common shares outstanding, diluted	8.51B+1055.9%	736.3M+9191.3%	7.9M-99.9%	5.84B

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.